Literature DB >> 12585167

[Study on effect of Salvia injection in treating primary nephrotic syndrome and on endothelin and serum interleukin-2 receptor in children].

Hua-ying Bao1, Hui-lan Yu, Lin Wang.   

Abstract

OBJECTIVE: To explore the effect and mechanism of Salvia Injection (SI) in treating primary nephrotic syndrome (PNS) in children.
METHODS: Forty-four PNS children were randomly divided into conventional steroid treated group (20 cases) and conventional plus SI intervention treated group (24 cases), the levels of serum endothelin (ET), soluable interleukin-2 receptor (sIL-2R) were observed.
RESULTS: Before treatment, plasma ET and sIL-2R in PNS children were higher than those in healthy children significantly (P < 0.01). After treatment, the ET and sIL-2R levels were all obviously improved in both treated groups (P < 0.05) and the improvement in the conventional plus SI intervention treated group was more obvious, the difference between the two treated groups after treatment was significant (P < 0.05).
CONCLUSION: Conventional treatment supplemented with SI could more effectively improve the levels of plasma ET and SIL-2R in treating PNS children, and hence alleviate the damage of renal tissue.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12585167

Source DB:  PubMed          Journal:  Zhongguo Zhong Xi Yi Jie He Za Zhi        ISSN: 1003-5370


  2 in total

Review 1.  Efficacy and Safety of Salvia miltiorrhiza for Treating Chronic Kidney Diseases: A Systematic Review and Meta-Analysis.

Authors:  Wei Zhang; Jun Li; Pan Yang; Gaoqiang Wang; Yanli Yue; Yuanfang Zhong; Hanyin Liu; Dingkun Gui; Youhua Xu; Niansong Wang
Journal:  Evid Based Complement Alternat Med       Date:  2022-06-14       Impact factor: 2.650

2.  A system-level investigation into the mechanisms of Chinese Traditional Medicine: Compound Danshen Formula for cardiovascular disease treatment.

Authors:  Xiuxiu Li; Xue Xu; Jinan Wang; Hua Yu; Xia Wang; Hongjun Yang; Haiyu Xu; Shihuan Tang; Yan Li; Ling Yang; Luqi Huang; Yonghua Wang; Shengli Yang
Journal:  PLoS One       Date:  2012-09-04       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.